Fleming 2002

1 Treatments

Studied treatment  metformin 850 mg BID

Control treatment  placebo

Concomittant treatments  -

Women (%)  -

Age (mean), years  -

2 Patients

Patients  PCO

Inclusion criteria  -

Exclusion criteria  -

Weight (kg)  -

Body-mass index (kg/m2)  -

Waist circumference (cm)  -

obesity  -

Family history of diabetes mellitus (%)  -

Definitions of impaired glucose tolerance and type 2 diabetes  -

3 Methods

Blinding  -

Design  -

Centers  -

Geographical area  -

Sizes  45/47

fasting plasma glucose (mmol/L)  -
2-h plasma glucose (mmol/L) –

Dyslipidaemia –

2hPG (>9.4–11.0 mmol/L) –

4 Results

<table>
<thead>
<tr>
<th>Endpoint</th>
<th>T1</th>
<th>T0</th>
<th>d</th>
<th>95% CI</th>
</tr>
</thead>
<tbody>
<tr>
<td>hospitalization for heart failure</td>
<td>-9</td>
<td>-9</td>
<td>NA</td>
<td>-</td>
</tr>
<tr>
<td>death</td>
<td>-9</td>
<td>-9</td>
<td>NA</td>
<td>-</td>
</tr>
<tr>
<td>CV death</td>
<td>-9</td>
<td>-9</td>
<td>NA</td>
<td>-</td>
</tr>
<tr>
<td>CV death, MI, stroke</td>
<td>-9</td>
<td>-9</td>
<td>NA</td>
<td>-</td>
</tr>
<tr>
<td>diabetes</td>
<td>-45</td>
<td>-47</td>
<td>NA</td>
<td>-</td>
</tr>
<tr>
<td>fatal and non fatal MI</td>
<td>-9</td>
<td>-9</td>
<td>NA</td>
<td>-</td>
</tr>
<tr>
<td>normoglycemia</td>
<td>-9</td>
<td>-9</td>
<td>NA</td>
<td>-</td>
</tr>
<tr>
<td>fatal and non fatal stroke</td>
<td>-9</td>
<td>-9</td>
<td>NA</td>
<td>-</td>
</tr>
<tr>
<td>cardiovasculaire events</td>
<td>-9</td>
<td>-9</td>
<td>NA</td>
<td>-</td>
</tr>
</tbody>
</table>

5 References

Fleming R, Hopkinson ZE, Wallace AM, Greer IA, Sattar N Ovarian function and metabolic factors in women with oligomenorrhea treated with metformin in a randomized double blind placebo-controlled trial. J Clin Endocrinol Metab 2002;87:569-74 [11836287]